Home › Research › Cognitive tests and assessment
Rate of progression differs in frontotemporal dementia and Alzheimer disease
Rascovsky K, Salmon DP, Lipton AM, Leverenz JB, DeCarli C, Jagust WJ, Clark CM, Mendez MF et al.. Neurology, 2005-08-01
Topic: Risk, prevention and care in population studies
Objective To compare survival and rates of cognitive and functional decline in patients with autopsy-confirmed frontotemporal dementia (FTD) and Alzheimer disease (AD) in a large multicenter study. Background Despite advances in the clinical characterization of FTD, little is known about its rate of progression. Characterizing survival and rate of decline in FTD is important because it can provide prognostic guidelines and benchmarks to use in the evaluation of disease-modifying drugs.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rascovsky, K., Salmon, D. P., Lipton, A. M., Leverenz, J. B., DeCarli, C., Jagust, W. J., et al. (2005). Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology. https://doi.org/10.1212/01.wnl.0000171343.43314.6e
Vancouver
Rascovsky K, Salmon DP, Lipton AM, Leverenz JB, DeCarli C, Jagust WJ, et al. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology. 2005. doi:10.1212/01.wnl.0000171343.43314.6e. PMID: 16087904.
BibTeX
@article{rascovsky2005-16087904,
author = {Rascovsky, K. and Salmon, D. P. and Lipton, A. M. and Leverenz, J. B. and DeCarli, C. and Jagust, W. J. and Clark, C. M. and Mendez, M. F. and others},
title = {{Rate of progression differs in frontotemporal dementia and Alzheimer disease}},
journal = {Neurology},
year = {2005},
doi = {10.1212/01.wnl.0000171343.43314.6e},
pmid = {16087904},
url = {https://doi.org/10.1212/01.wnl.0000171343.43314.6e}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Background Despite advances in the clinical characterization of FTD, little is known about its rate of progression.
- Characterizing survival and rate of decline in FTD is important because it can provide prognostic guidelines and benchmarks to use in the evaluation of disease-modifying drugs.
- Methods Seventy patients with FTD and 70 patients with AD who were followed by seven Alzheimer disease research centers until confirmation of diagnosis at autopsy were matched for overall age, education, and Mini-Mental State Examination (MMSE) score at initial evaluation.
- Survival and rates of cognitive and functional decline were compared.
Why it matters
This multicenter study compared survival and rates of cognitive and functional decline in 70 patients with autopsy-confirmed frontotemporal dementia and 70 with Alzheimer's disease. It is about comparing disease progression and does not test any treatment, so it says nothing about curing or preventing Alzheimer's disease.
Study details
- Participants70
- Evidence strengthLow
How this study scored 56/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2005 — older than 20 years, still counted |
| Sample size | 1 / 4 | 70 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 184 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.0 citations a year over 23 year(s) since 2005 |
| Impact for its field and year | 3 / 6 | Cited 7.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 17 other studies in this library |
| Still being cited | 2 / 4 | Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Douglas R Galasko: h-index 123 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | University of Washington: institution h-index 3,540 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 16087904) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
17 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Cognitive tests and assessment
Also tagged “lewy”
1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.